Recently, Fedele et al. showed that protein-tyrosine phosphatase (SHP2) inhibitor SHP099 in combination with MEK inhibitor (either trametinib or selumetinib) blocked proliferation of multiple cancer cell lines, including OC, and prevented the development of adaptive resistance to MEK inhibitors [47]. Here, MAP2K7 is linked to cancer.